


# Fall 2001

- 1 **Letter from Rick Doblin, Ph.D., MAPS President**
- 3 **MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder (PTSD): Protocol Submitted to FDA on October 1, 2001**  
By Michael Mithoefer, M.D.
- 
- 5 **Preliminary Report - Chronic Cannabis Use in the Compassionate Investigational New Drug Program: An Examination of Benefits and Adverse Effects of Legal Clinical Cannabis**  
By Ethan Russo, Mary Lynn Mathre, Al Byrne, Robert Velin, Paul J. Bach, and Juan Sanchez-Ramos
- 
- 6 **MAPS Medical Marijuana Production Facility: A Progress Report**  
By Rick Doblin, Ph.D.
- 
- 8 **Research at Harvard Medical School**  
By John H. Halpern, M.D.
- 
- 10 **Interview with Dr. John Halpern**  
By Valerie L. Mojeiko
- 
- 12 **A Dissertation On The Constructive (Therapeutic and Religious) Use of Psychedelics: A Request for Support**  
By Hans C. Ossebaard
- 
- 14 **Working with Difficult Psychedelic Experiences**  
By Brandy Doyle
- 
- 18 **Holotropic Breathwork with Dr. Stanislav Grof**  
By Valerie L. Mojeiko
- 
- 22 **Stanislav Grof interviews Dr. Albert Hofmann Esalen Institute, Big Sur, California, 1984**  
By Dr. Stanislav Grof
- 
- 36 **The Highest Art: the Art of Combining Traditional Consciousness Techniques with Advancing Consciousness Technologies in Sacred Psychedelic Practice**  
By Brother Andrew H.
- 
- 43 **Meditation and Psychedelics**  
By Vanja Palmers
- 
- 45 **Time**  
By Dr. Roy Mathew
- 
- 48 **Being Outside the Dominion of Time**  
By Benny Shanon
- 
- 53 **Bulletin Announcements**
- 54 **MAPS Membership Pages**
- Back Cover*     **In Memoriam: John C. Lilly**

MAPS (Multidisciplinary Association for Psychedelic Studies) is a membership-based organization working to assist psychedelic researchers around the world design, obtain governmental approval, fund, conduct and report on psychedelic research in humans. Founded in 1986, MAPS is an IRS approved 501 (c)(3) non-profit corporation funded by tax-deductible donations. MAPS has previously funded basic scientific research into the safety of MDMA (3,4-methylene-dioxymethamphetamine, Ecstasy) and has opened a Drug Master File for MDMA at the U.S. Food and Drug Administration. MAPS is now focused primarily on assisting scientists to conduct human studies to generate essential information about the risks and psychotherapeutic benefits of MDMA, other psychedelics, and marijuana, with the goal of eventually gaining government approval for their medical uses. Interested parties wishing to copy any portion of this publication are encouraged\* to do so and are kindly requested to credit MAPS including name and address. The MAPS Bulletin is produced by a small group of dedicated staff and volunteers. Your participation, financial or otherwise, is welcome.

©2001 Multidisciplinary Association for Psychedelic Studies, Inc. (MAPS)  
2105 Robinson Avenue,  
Sarasota, FL 34232  
Phone: 941-924-6277  
Toll-Free: 888-868-MAPS  
Fax: 941-924-6265  
E-mail: info@maps.org  
Web: www.maps.org



Edited by Rick Doblin and Maggie Hall  
Layout/Design by Mercedes Paulino